Open main menu

Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.[1]

Clinical data
ATC code
Pharmacokinetic data
Elimination half-life3.6–10.4 min
CAS Number
  • none
Chemical and physical data
Molar mass55597.4 g/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.[1] It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug approved as an enzyme replacement therapy.[1]

It was approved by the FDA in 1991.[2] It has been withdrawn from the market[3][4] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture[1] (see imiglucerase).


  1. ^ a b c d Deegan, PB; Cox, TM (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Des Devel Ther. 6: 81–106. doi:10.2147/DDDT.S14395. PMC 3340106. PMID 22563238.
  2. ^ World Health Organization. Regulatory Matters WHO Drug Information 5:3 1991. p 123
  3. ^ Aetna. Last reviewed 8 August 2014 Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders
  4. ^ FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List

External linksEdit